“社恐”福音?抗焦慮藥物取得進展,VistaGen一夜暴升677%
在國內醫藥反腐,醫藥相關板塊個股大跌之際,美股醫藥公司Vistagen一夜翻了10倍,盤初一度暴升1370%,盤中多次觸發熔斷,目前收升676.79%。

VistaGen是一家臨牀階段的生物製藥公司,旨在改變焦慮、抑鬱等疾病患者的治療環境。
抗焦慮鼻噴劑試驗結果喜人
消息面上,8月7日,Vistagen公佈了PH94B(fasedienol)治療社交恐懼症的III期PALISADE-2研究的積極結果。

據瞭解,PH94B是一款用於治療社交焦慮症(俗稱:社恐)的快速起效(約10-15分鐘)鼻噴劑。其作用機制不同於現有的抗抑鬱藥和苯二氮卓類藥物,該藥物不直接激活GABA-A受體,也不直接作用於大腦的中樞神經系統。因此PH94B不需要全身攝取或引起苯二氮卓類的副作用和安全性問題。
根據Vistagen官網顯示,在美國,有超過 2500 萬人患有社交焦慮症,全球有2.64億人受社交焦慮障礙影響。

Vistagen首席執行官Shawn Singh表示:“我們很高興PALISADE-2III期試驗的這些令人信服的最新結果證實了社交焦慮症2期研究的結果,並強調了法二烯醇及其新穎獨特的作用機制的潛力,它可以改變美國2500多萬社交焦慮症患者和世界上數百萬受影響的人的可能“。
“作為一類新的藥物,我們的pherine鼻噴霧劑管道有可能改變眾多治療領域的治療格局。在這類藥物中,法二烯醇的潛力,正如本次3期試驗所證明的那樣,為20多年來第一種用於SAD患者的全新藥物奠定了基礎。”他進一步表示。
注意到,就在一年多前,VistaGen的PH94B鼻噴霧劑在一項三期研究中失敗,錯過了治療成人社交焦慮症的主要終點。該公司當時表示將繼續開發這種噴霧劑。
今天第二項三期臨牀獲得成功意義重大,意味着超過20年以來社恐領域首款新機制藥物的里程碑進展。
2023全年虧損59.25百萬美元
財務數據方面,Vistagen6月28日發佈財報顯示,公司截至2023年3月31日,公司2023全年虧損5924.77萬美元,上年同期虧損4776.24萬美元;總營收僅有22.73萬美元,同比減少120.5%。
從資產負債表來看,Vistagen Therapeutics Inc(VTGN.US)總負債9.01百萬美元,其中短期債務592600.00美元,資產負債比為2.35,流動比率為3.82。
公司股東名單中,投資巨頭貝萊德(BlackRock)去年年底曾經持有該公司超過5%的股份,但截止6月31日,貝萊德已經不再是持股超過5%的股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.